473 related articles for article (PubMed ID: 18794799)
21. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer.
Dougherty MK; Schumaker LM; Jordan VC; Welshons WV; Curran EM; Ellis MJ; El-Ashry D
Cancer Biol Ther; 2004 May; 3(5):460-7. PubMed ID: 15020841
[TBL] [Abstract][Full Text] [Related]
22. Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
Proverbs-Singh T; Feldman JL; Morris MJ; Autio KA; Traina TA
Endocr Relat Cancer; 2015 Jun; 22(3):R87-R106. PubMed ID: 25722318
[TBL] [Abstract][Full Text] [Related]
23. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.
Marconett CN; Morgenstern TJ; San Roman AK; Sundar SN; Singhal AK; Firestone GL
Cancer Biol Ther; 2010 Aug; 10(4):397-405. PubMed ID: 20574166
[TBL] [Abstract][Full Text] [Related]
24. Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth.
Fallatah MM; Liu S; Sevigny MB; Zou H; Louie MC
Cancer Lett; 2017 Nov; 408():82-91. PubMed ID: 28844711
[TBL] [Abstract][Full Text] [Related]
25. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
[TBL] [Abstract][Full Text] [Related]
26. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
[TBL] [Abstract][Full Text] [Related]
27. [Targeted degradation of androgen receptors in androgen-independent prostate cancer cells: an experimental study].
Shi YF; Tang YQ; Sun XW; Yu DJ; Han BM; Hong Y; Xia SJ
Zhonghua Nan Ke Xue; 2009 Dec; 15(12):1059-63. PubMed ID: 20180412
[TBL] [Abstract][Full Text] [Related]
28. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
[TBL] [Abstract][Full Text] [Related]
29. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
30. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
31. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers.
Ko YJ; Balk SP
Curr Pharm Biotechnol; 2004 Oct; 5(5):459-70. PubMed ID: 15544494
[TBL] [Abstract][Full Text] [Related]
32. PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer.
Zhang X; Zhang Z; Xue X; Fan T; Tan C; Liu F; Tan Y; Jiang Y
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1109-1118. PubMed ID: 36407946
[TBL] [Abstract][Full Text] [Related]
33. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
34. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
35. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2.
Riching KM; Schwinn MK; Vasta JD; Robers MB; Machleidt T; Urh M; Daniels DL
SLAS Discov; 2021 Apr; 26(4):560-569. PubMed ID: 33190579
[TBL] [Abstract][Full Text] [Related]
36. Docosahexaenoic acid induces proteasome-dependent degradation of estrogen receptor alpha and inhibits the downstream signaling target in MCF-7 breast cancer cells.
Lu IF; Hasio AC; Hu MC; Yang FM; Su HM
J Nutr Biochem; 2010 Jun; 21(6):512-7. PubMed ID: 19369047
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.
Lu M; Liu T; Jiao Q; Ji J; Tao M; Liu Y; You Q; Jiang Z
Eur J Med Chem; 2018 Feb; 146():251-259. PubMed ID: 29407955
[TBL] [Abstract][Full Text] [Related]
38. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
39. IL-1-conferred gene expression pattern in ERα
Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
[TBL] [Abstract][Full Text] [Related]
40. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
